BioSpace News Archive

Three IPO aspirants have stepped up at the start of the new year: CinCor Pharma, Amylyx and Applied UV

Applied Therapeutics said it is holding off on a New Drug Application after discussions with the FDA, which appears to require additional clinical data.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

The report focuses on current and emerging trends in the healthcare industry such as incorporation of IoT and ML to enhance efficiency of medical products.

Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), today announced that it has entered into an agreement with Asklepios BioPharmaceutical, Inc. (“AskBio”), a fully integrated AAV gene therapy company and a fully owned subsidiary of Bayer AG dedicated to developing medicines that improve the quality of life for patients with genetic diseases.

Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the 40th Annual JP Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 PM ET.

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 pm ET.

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of corporate performance in 2021 and major goals for 2022 at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15 pm ET.

Berkeley Lights, Inc., a leader in digital cell biology, announced the Company will be participating virtually in the upcoming 40th Annual J.P. Morgan Healthcare Conference.